Health Care & Life Sciences » Pharmaceuticals | United Laboratories International Holdings Ltd.

United Laboratories International Holdings Ltd. | Cash Flow

Fiscal year is January-December. All values HKD Millions.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
901
664
235
155
80
940
Depreciation, Depletion & Amortization
575
707
814
824
904
878
Other Funds
101
75
61
34
60
168
Funds from Operations
621
1,198
1,057
658
1,171
1,650
Changes in Working Capital
443
194
431
430
510
428
Net Operating Cash Flow
1,065
1,392
1,488
1,088
660
1,223
Capital Expenditures
2,046
692
772
541
547
Sale of Fixed Assets & Businesses
50
83
90
107
6
Purchase/Sale of Investments
2,253
-
1
-
-
Net Investing Cash Flow
1,604
1,183
629
435
484
Issuance/Reduction of Debt, Net
1,054
198
851
428
1,007
Net Financing Cash Flow
953
273
913
462
946
Net Change in Cash
435
78
98
1,033
773
Free Cash Flow
981
700
765
624
132
Other Sources
9
2,836
55
1
56
Exchange Rate Effect
21
13
45
82
2
Other Uses
1,869
3,410
-
1
-

About United Laboratories International Holdings

View Profile
Address
6 Fuk Wang Street
Hong Kong
Hong Kong
Employees -
Website http://www.tul.com.cn
Updated 07/08/2019
United Laboratories International Holdings Ltd. operates as an investment company, which engages in the manufacturing and sale of medicines, and the bulk and intermediate products used to produce finished goods. It operates through the following segments: Intermediate Products, Bulk Medicine, and Finished Products. The Intermediate Products segment offers two major products, such as T-Octylammonium Clavulanate and 6-APA.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.